ONCY vs. AFMD, ETON, BTAI, CMRX, QTTB, PMVP, HOOK, YS, SPRO, and IFRX
Should you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Affimed (AFMD), Eton Pharmaceuticals (ETON), BioXcel Therapeutics (BTAI), Chimerix (CMRX), Q32 Bio (QTTB), PMV Pharmaceuticals (PMVP), Hookipa Pharma (HOOK), YS Biopharma (YS), Spero Therapeutics (SPRO), and InflaRx (IFRX). These companies are all part of the "pharmaceutical preparations" industry.
Affimed (NASDAQ:AFMD) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, community ranking, institutional ownership and risk.
30.8% of Affimed shares are held by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are held by institutional investors. 3.8% of Affimed shares are held by insiders. Comparatively, 0.1% of Oncolytics Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Affimed presently has a consensus target price of $45.00, indicating a potential upside of 794.63%. Oncolytics Biotech has a consensus target price of $4.00, indicating a potential upside of 266.97%. Given Oncolytics Biotech's higher possible upside, analysts clearly believe Affimed is more favorable than Oncolytics Biotech.
Affimed has a beta of 2.05, indicating that its stock price is 105% more volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.93, indicating that its stock price is 93% more volatile than the S&P 500.
Oncolytics Biotech has a net margin of 0.00% compared to Oncolytics Biotech's net margin of -1,280.27%. Affimed's return on equity of -105.97% beat Oncolytics Biotech's return on equity.
Affimed received 278 more outperform votes than Oncolytics Biotech when rated by MarketBeat users. Likewise, 69.92% of users gave Affimed an outperform vote while only 68.16% of users gave Oncolytics Biotech an outperform vote.
Oncolytics Biotech has lower revenue, but higher earnings than Affimed. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.
In the previous week, Affimed had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 4 mentions for Affimed and 3 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.30 beat Affimed's score of 0.00 indicating that Affimed is being referred to more favorably in the media.
Summary
Affimed beats Oncolytics Biotech on 11 of the 16 factors compared between the two stocks.
Get Oncolytics Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Oncolytics Biotech Competitors List
Related Companies and Tools